Investigating immunogenicity to biopharmaceutics version 2
Research type
Research Study
Full title
Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK
IRAS ID
126303
Contact name
Claudia Mauri
Contact email
Sponsor organisation
University College London Hospital NHS Trust
Research summary
It is thought that one of the reasons that patients do not respond, or lose response, to treatment with biopharmaceutical drugs (BP) is the development of anti-drug antibodies (ADA).The ability to predict which patients will develop these antibodies and then prevent ADA from having a negative effect on drug function, are therefore major goals for the future of BP drug development. Our research aims to identify and characterize ADA, to facilitate their detection in clinical practice, and thus to optimize patient response to treatment.
We will be recruiting patients who are starting on BP drugs, collecting clinical data and testing for ADA, as well as other immune cell functions. We will look for correlations to allow us to optimize the predicition of drug response, and tailor individual patient treatment plans accordingly.REC name
London - City & East Research Ethics Committee
REC reference
14/LO/0506
Date of REC Opinion
16 Jun 2014
REC opinion
Further Information Favourable Opinion